Revolution Medicines, Inc.: management transactions · United States · SEC (Form 4)

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ market, and it is based in Redwood City, California, in the United States. For international investors, the company represents a focused precision-oncology story rather than a broad commercial pharmaceutical platform. Its core strategy is to develop therapies for so-called RAS-addicted cancers, tumors whose growth is driven by oncogenic RAS pathway mutations. That scientific focus places Revolution Medicines in a specialized, research-intensive segment of biotech, where valuation is largely determined by clinical execution and data quality. The company was founded in 2014 and has spent the intervening years building a pipeline around the long-standing challenge of inhibiting RAS biology. Its programs center on RAS(ON) inhibitors designed to target active RAS proteins and specific oncogenic variants. The lead candidate is daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor. Other major assets include elironrasib (RMC-6291), a G12C-selective inhibitor; zoldonrasib (RMC-9805), a G12D-selective inhibitor; and RMC-5127, a G12V-selective inhibitor. The company is also pursuing additional opportunities in other RAS mutation settings, including Q61H and G13C. From a competitive perspective, Revolution Medicines stands out because it is trying to address multiple mutation hotspots within one of oncology’s most commercially and medically important pathways. Its opportunity set is concentrated in high-unmet-need cancers such as pancreatic cancer and certain lung cancer populations. As a result, the investment case is highly catalyst-driven: the company’s trajectory depends on clinical readouts, durability of response, safety/tolerability, regulatory engagement, and ultimately the ability to turn early signals into approvable, differentiated therapies. Recent developments have reinforced that profile. In April 2026, Revolution Medicines reported updated Phase 1/2 data for daraxonrasib in first-line metastatic pancreatic cancer and also highlighted positive pivotal Phase 3 RASolute 302 results in previously treated metastatic pancreatic cancer. The company also completed a large capital raise in April 2026 through an upsized common-stock and convertible-note offering, underscoring the funding intensity typical of late-stage oncology development. In May 2026, it reported first-quarter 2026 financial results and continued to emphasize progress across its RAS(ON) pipeline.